Colistin and polymyxin B remain part of the last line of antibiotics for multidrug-resistant Gram-negative bacteria, such as carbapenem-resistant Enterobacteriaceae. Current joint EUCAST-CLSI recommendations are for broth microdilution (BMD) to be performed for MIC testing of colistin. Commercial susceptibility testing methods were evaluated and compared against the reference BMD, using a susceptibility breakpoint of Յ2 mg/liter for both colistin and polymyxin B. Seventy-six Enterobacteriaceae were included, of which 21 were mcr-1 positive (18 Escherichia coli isolates, 2 Klebsiella pneumoniae isolates, and 1 Enterobacter aerogenes isolate). Rates of essential agreement (EA) of colistin test results between BMD and Vitek 2, Sensititre, and Etest were 93.4%, 89.5%, and 75.0%, respectively. Rates of EA of polymyxin B test results between BMD and Vitek 2, Sensititre, and Etest were 96.1%, 96.1%, and 48.7%, respectively. A positive MIC correlation with a categorical agreement of Ͼ90% was achieved for Sensititre (colistin Spearman's ϭ 0.863, and polymyxin B Spearman's ϭ 0.877) and Vitek 2 (polymyxin B [only] Spearman's ϭ 0.8917). Although a positive MIC correlation (Spearman's ϭ 0.873) with the reference method was achieved for colistin testing with Vitek 2, categorical agreement was Ͻ90%, with very major error rates of 36%. Correlation with the Etest MIC was lower, with very major error rates of 12% (colistin) and 26.1% (polymyxin B). MicroScan (colistin) categorical agreement was 88.2%, with a very major error rate of 4%. Colistin MICs for 15 of the 21 mcr-1-positive isolates were Ͼ2 mg/liter, and polymyxin MICs for 17 of them were Ͼ2 mg/liter by broth microdilution. The use of a lower breakpoint of Յ1 mg/liter further improves detection of mcr-1 for all testing methods. However, further data on the correlation between MICs and clinical outcome are required to determine the most suitable breakpoint to guide clinical management.KEYWORDS colistin, polymyxin B, susceptibility testing, mcr-1 M ultidrug-resistant organisms (MDROs) represent a progressive burden on health care systems globally. Carbapenem-resistant Enterobacteriaceae (CRE) are now reported worldwide. CRE infections are difficult to treat, and there are limited options available. The polymyxins (colistin and polymyxin B) are antibiotics which are used for treating infections with CRE. Polymyxins initially fell out of favor among clinicians due to concerns over high rates of nephrotoxicity and neurotoxicity (1). In recent years, the use of polymyxins has been on the rise, with increasing rates of CRE infection.